3 Undervalued Pharmaceuticals Stocks for Thursday, October 15
Discover the top 3 undervalued Pharmaceuticals stocks for Thursday, October 15 based on AAII’s Stock Grades.Michael Rose
| SECTOR | INDUSTRY |
| Health Care | Pharmaceuticals |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Michael Rose
This week, we use AAII’s A+ Investor Stock Grades to provide insight into three pharmaceutical stocks.
Rosalio Madrigal
Cynthia McLaughlin
Tudor Pop
Michael Rose
| Share Statistics | AMPH | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $1,211.9 | $419.8 | 48% |
|
| Shares Out (Mil) | 43.4 | 43.5 | 44% |
|
| Institutional Ownership | 86.8% | 80.9% | 55% |
|
| Float (Mil) | 31.3 | 46.7 | 37% |
|
| Beta | na | 0.71 | na |
|
| Avg Daily Volume (000s) | 511 | 281 | 58% |
|
| Price Change (52-week) |
12.6% | 53.5% | 62% |
|
| Growth | AMPH | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 15.5% | 6.1% | 74% |
|
| Net Income (5yr) | 133.9% | (1.8%) | 99% |
|
| EPS (5yr) | 132.3% | 14.9% | 100 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | 0.0% | (15.1%) | 64% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 7 | 7 | 7 | |
| Current EPS | $0.859 | $2.962 | $3.172 | |
| Month Ago EPS | $0.865 | $2.972 | $3.182 | |
| # Rev Up | 1 | 0 | 0 | |
| # Rev Down | 0 | 1 | 1 | |
| Three Months Ago EPS | $0.852 | $2.966 | $3.049 | |
| Year/Year Chg | (1.3%) | 45.9% | 65.9% | |
| Financials | AMPH | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $746 | $301 | 46% |
|
| Net Income (TTM) (Mil) | $99 | ($11) | 60% |
|
| EPS (TTM) | $2.231 | ($0.600) | 73% |
|
| Operating Cash Flow (TTM) (Mil) | $175 | ($6) | 57% |
|
| Net Cash Flow (TTM) (Mil) | ($12) | $2 | 30% |
|
| Long-Term Debt (Q1) (Mil) | $681 | $6 | 62% |
|
| Enterprise Value (Q1) (Mil) | $1,638 | $446 | 47% |
|
| Valuation | AMPH | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.49 | 2.01 | 43% |
|
| P/E | 13.1 | 21.4 | 34% |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | 0.1 | 1.1 | 3% |
|
| Ratios | AMPH | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 46.8% | 67.7% | 58% |
|
| Net Margin | 13.3% | 3.6% | 69% |
|
| ROA | 5.9% | (22.2%) | 74% |
|
| ROE | 12.4% | (21.5%) | 64% |
|
| Liabilities to Assets | 52.4% | 31.5% | 45% |
|
| F-Score | 5 | 3 | 50% |
|
Amphastar Pharmaceuticals, Inc. did not pass any screens on 11/6/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors